All Oncology News

Alison R. Sehgal, MD, discusses the latest developments with CAR T-cell therapy in lymphomas.

The FDA has granted an accelerated approval to selinexor in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma who have received ≥4 prior therapies and whose disease is refractory to ≥2 proteasome inhibitors, ≥2 immunomodulatory agents, and a CD38-targeted monoclonal antibody.

Andrew J. Cowan, MD, discussed pivotal trials in multiple myeloma and potential for new treatments in the future.

A weekly regorafenib (Stivarga) dose-escalation strategy beginning at 80 mg and ending at 160 mg is an appropriate and potentially optimal approach for previously treated patients with metastatic colorectal cancer.

Vivian G. Oehler, MD, discusses the important aspects of TKI discontinuation and the patient factors that would warrant such an approach.

Vivian G. Oehler, MD, highlights ongoing developments in myeloproliferative neoplasms and shares her hopes for the future.

The CanStem111P trial, which was evaluating the combination of napabucasin, weekly nab-paclitaxel (Abraxane), and gemcitabine compared with nab-paclitaxel/gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma, will be discontinued due to futility.

Chaitra S. Ujjani, MD, discusses the various therapeutic classes and agents that are showing the most promise in the field of follicular lymphoma.

Mary-Elizabeth Percival, MD, discusses advances and challenges with targeted agents in acute myeloid leukemia and remaining questions in the field.

Mazyar Shadman, MD, MPH, discusses earlier use of CAR T-cell therapy in lymphoma, the impact of approved products on future development, and recent data with chemotherapy-free and time-limited therapy in chronic lymphocytic leukemia.

Meletios A. Dimopoulos, MD, discusses where the triplet combination of elotuzumab (Empliciti), pomalidomide (Pomalyst), and low-dose dexamethasone fits into the treatment paradigm of relapsed/refractory multiple myeloma and shared unanswered questions that remain in the space.

The European Commission approved cemiplimab (Libtayo) for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation.

Larry Kwak, MD, PhD, has been appointed the deputy director of City of Hope's Hematologic Malignancies and Stem Cell Transplantation Institute.

Kim Chi, MD, discusses how the next-generation androgen receptor inhibitor apalutamide in combination with androgen deprivation therapy could be a new standard of care for patients with metastatic castration-sensitive prostate cancer.

The FDA has approved a supplemental new drug application to expand the use of avatrombopag to include the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to prior therapy.

An application has been submitted to the FDA for neratinib for use in combination with capecitabine for the third-line treatment of patients with HER2-positive metastatic breast cancer.

Ryan J. Sullivan, MD, discusses the success with dabrafenib (Tafinlar) plus trametinib (Mekinist) and highlights the potential added benefit of spartalizumab in BRAF-mutant with melanoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended expanding the indications of ibrutinib (Imbruvica) to include use in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia, and also in combination with rituximab (Rituxan) for the treatment of adult patients with Waldenström’s macroglobulinemia.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the frontline combination of atezolizumab (Tecentriq) plus nab-paclitaxel (Abraxane) for the treatment of adult patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Thomas E. Stinchcombe, MD, discusses the numerous ALK inhibitors available in the treatment of ALK-positive non–small cell lung cancer, ongoing efforts to combat resistance, and sequencing challenges that have emerged.

The FDA has approved PF-06439535, a bevacizumab biosimilar, for the treatment of patients with metastatic colorectal cancer; unresectable, locally advanced, recurrent, or metastatic nonsquamous non–small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent, or metastatic cervical cancer.

The FDA has approved the combination of daratumumab with lenalidomide and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation.

Jerald P. Radich, MD, the methods that are used to measure minimal residual disease and the work being done to standardize its use in acute lymphoblastic leukemia.

Durvalumab combined with standard etoposide and platinum-based chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared with standard chemotherapy alone as a first-line treatment in patients with extensive-stage small cell lung cancer, meeting the primary endpoint of the phase III CASPIAN trial (NCT03043872).

MAPK/ERK gene alterations, primarily receptor tyrosine kinases, BRAF, and CDK4/6 amplifications, were found to be present in more than half of patients with heavily pretreated metastatic prostate cancer.

Switch maintenance treatment with pembrolizumab improved progression-free survival in patients with metastatic urothelial cancer who have stable disease following frontline platinum-based chemotherapy.

Karim Fizazi, MD, PhD, discusses the impact of darolutamide on pain progression and quality of life in patients with nonmetastatic castration-resistant prostate cancer.

Yee Chung Cheng, MD, discusses the importance of integrating neoadjuvant and adjuvant trial data into practice in order to optimize outcomes for patients with early-stage HER2-positive breast cancer.

Hossein Borghaei, MD, highlights long-term single-agent pembrolizumab (Keytruda) data and the overall state of immunotherapy in non–small cell lung cancer, as well as the prospect of making clinical trial eligibility less restrictive.

Jennifer Woyach, MD, discusses the 3-year follow-up from the single-arm study of the combination of acalabrutinib (Calquence) and obinutuzumab (Gazyva) showcase the efficacy of the regimen in both patients with treatment-naïve and relapsed/refractory chronic lymphocytic leukemia and the future of treatment in the space.